A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes.
about
Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitusEfficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysisCardiovascular effects of basal insulinsSafety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysisExenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study.Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials.Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value.Insulin glargine compared to NPH among insulin-naïve, U.S. inner city, ethnic minority type 2 diabetic patients.Diabetes: glycaemic control in type 2 (drug treatments).Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents--a randomized, prospective, crossover, open clinical trial.Initiating insulin in patients with type 2 diabetes.New strategies in insulin treatment: analogues and noninvasive routes of administration.Long-Acting Insulin Analogues for the Treatment of Diabetes Mellitus: Meta-analyses of Clinical OutcomesInsulin detemir: from concept to clinical experience.Basal insulin treatment in type 2 diabetes.Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus.An update on the long-acting insulin analogue glargine.Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial.Nocturnal hypoglycemia: answering the challenge with long-acting insulin analogs.Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study.Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis.Optimum management of type 2 diabetes--timely introduction, optimization and intensification of basal insulin.Insulin glargine in type 2 diabetes in everyday clinical practice: 7 years experience.Insulin therapy in elderly patients with type 2 diabetes: the role of insulin glargine.Insulin management in overweight or obese type 2 diabetes patients: the role of insulin glargine.Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine.Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.Combined randomised controlled trial experience of malignancies in studies using insulin glarginePractical Focus on American Diabetes Association/European Association for the Study of Diabetes Consensus Algorithm in Patients with Type 2 Diabetes Mellitus: Timely Insulin Initiation and Titration (Iran-AFECT).Starting bedtime glargine versus NPH insulin in poorly controlled type 2 diabetic patients with various hyperglycemia types (fasting type or postprandial type).Differences between long-acting insulins for the treatment of type 2 diabetes.Combining basal insulin analogs with glucagon-like peptide-1 mimetics.Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis.Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus.Pharmacologic treatment of type 2 diabetes: injectable medications.Efficacy and safety of switching from basal insulin to once-daily insulin degludec/insulin aspart in Japanese patients with inadequately controlled type 2 diabetes: A 4-week, randomized, open-label, treat-to-target study.The utility of insulin glargine in the treatment of diabetes mellitus.Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin.Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.
P2860
Q24245192-EBB1C172-C6B7-465E-921E-B35B934655B7Q24656013-4B98548E-91C6-46EA-B97D-BD8FC0F53AB2Q26800249-3727A8D9-8417-4D33-AC9F-1782AF5E63B6Q28078467-1BD94D67-0887-46F5-9AE7-BCDAA69F595BQ33606579-33CFAE87-7FEE-4456-8CC3-8A67263C8928Q33871459-70D1925A-EDBA-4AC1-AD14-3A1E45297905Q34449820-B725D430-785D-45D2-806E-1F466F337D52Q34663438-39CB0635-D787-4D89-B1A0-0511F7F4A5D8Q34829290-7ECC4F2B-6689-4664-9B69-6357243A825AQ35694576-FD0AD414-1D82-4EB0-AE31-9C98623986E7Q35894554-6F759E11-BDF4-4A73-A80E-8A48A1A61219Q36089348-0FB0EFEE-955E-476E-ACC5-80C35A5031B2Q36137731-8B08DA56-689B-4677-BBE4-972F2A7D727AQ36382590-23136787-7F90-4048-834E-89FFF4464DEEQ36417426-3BA691FC-0FD8-4911-8849-A3B5E77A1DE6Q36521871-D3CDD9A8-7231-4F33-82A1-C6F7C4973F28Q36546691-FE854F77-9B0C-45DD-8253-D5658FC95B0BQ36712865-275FE01F-A920-4B72-B297-C4E674E02896Q36978852-EC619C98-13A7-4701-93AE-EAE570B9FB9EQ37087031-6773816C-8281-433E-9387-5DC0C18284DEQ37107135-EE1762E6-A187-4AD4-9B85-D985FC2FDBF2Q37199304-20B7E85E-602E-4CB5-9FD9-4BB8EB5C76F2Q37199311-7F1DC9DA-01D7-4AFA-879C-826F2A75627CQ37199315-08ED1648-C264-4373-AC71-7054B74ABD2CQ37199318-DF3001AB-750F-4087-8CFE-8EA9DCDEF52DQ37199322-B71FF988-B785-4E4E-B914-0523D2248C19Q37296843-C4ABE142-F580-42C5-A5F8-137D49F1083EQ37348811-7ACC56B9-DAFC-4736-B6B6-789273084EAFQ37418681-F7B654A8-FAAB-424D-A96B-352D17F62169Q37670097-A5F34498-E155-4965-8982-B7ACA3A0C78AQ37671870-06D029A5-F649-4528-992A-4D4A9983D494Q37773993-21D4FB23-C5CB-4A5C-8D5E-55373E2AEFD1Q37895271-FBC698E4-F675-4140-A195-09331E81E677Q37964744-D3ECB82D-87FB-454C-A9E9-135277533BE9Q38317168-4CCF4876-CBC0-4417-98FC-972210FC61FFQ38388602-C16C7D5C-9388-4EDC-876D-93D9363280A3Q42691318-E1C76923-E626-4294-AB5F-5B5B76DD5FE0Q44955647-CEC5AB84-F322-4AF0-B6CA-6F28105D5BB2Q45746133-271D7DAB-D06B-4295-BFF4-0985DBAC2192Q46691040-EAD3573C-BD88-4D57-AEEA-AE3B6E156219
P2860
A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
A one-year, randomised, multic ...... patients with type 2 diabetes.
@en
A one-year, randomised, multic ...... patients with type 2 diabetes.
@nl
type
label
A one-year, randomised, multic ...... patients with type 2 diabetes.
@en
A one-year, randomised, multic ...... patients with type 2 diabetes.
@nl
prefLabel
A one-year, randomised, multic ...... patients with type 2 diabetes.
@en
A one-year, randomised, multic ...... patients with type 2 diabetes.
@nl
P2093
P921
P356
P1476
A one-year, randomised, multic ...... patients with type 2 diabetes.
@en
P2093
Dressler A
Massi Benedetti M
P304
P356
10.1055/S-2003-39080
P577
2003-03-01T00:00:00Z